Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVCN

DatePrice TargetRatingAnalyst
More analyst ratings

$NVCN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Volato Announces Changes to Board Composition

    Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

    $BSX
    $SOAR
    $NVCN
    Medical/Dental Instruments
    Health Care
    Transportation Services
    Consumer Discretionary
  • Neovasc Shareholders Approve Acquisition by Shockwave Medical

    Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ:NVCN) (TSX:NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting").The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareholders o

    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care
  • Neovasc Shareholders Approve Acquisition by Shockwave Medical

    VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareh

    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care

$NVCN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NVCN
SEC Filings

See more

$NVCN
Financials

Live finance-specific insights

See more
  • Volato Announces Changes to Board Composition

    Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

    $BSX
    $SOAR
    $NVCN
    Medical/Dental Instruments
    Health Care
    Transportation Services
    Consumer Discretionary
  • Neovasc Announces Third Quarter Financial Results and Provides Corporate Update

    VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") ((NASDAQ, TSX:NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021. Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter. Continued enrollment in the COSIRA II pivotal trial, with enrollment expected to be complete in the first half of 2024 and initial data readout in the second half of 2024. In July, 2022, the Company re

    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care
  • Neovasc to Report Third Quarter Financial Results on November 10, 2022

    VANCOUVER and MINNEAPOLIS, Oct. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ ,  TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022. Interested parties may access the conference call by dialing (800) 458-4121 or (856) 344-9290 (International) and reference Conference ID 7304031. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc we

    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care

$NVCN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more